Axsome Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones00:51 · Ratings

Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says

MT NewswiresDec 31, 2024 21:53

Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125

Futu NewsDec 31, 2024 21:31 · Ratings

Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110

Futu NewsDec 31, 2024 21:31 · Ratings

Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124

Futu NewsDec 31, 2024 21:31 · Ratings

A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180

Futu NewsDec 31, 2024 21:00 · Ratings